Potential advantage of clinical exome sequencing in BRCA1/2-negative families: a retrospective study of a cohort of 500 patients at a high-risk for hereditary cancers.
Broader genetic testing beyond standard panels identifies disease-causing genes in families with hereditary cancer, potentially explaining previously unexplained family histories.
This retrospective Italian study of 500 BRCA1/2-negative hereditary cancer families demonstrates that clinical exome sequencing identifies actionable pathogenic variants in alternative cancer predisposition genes beyond BRCA1/2 in a substantial proportion of patients who otherwise receive no genetic diagnosis. These findings support expanding genetic testing from limited BRCA panels to clinical exome sequencing in high-risk hereditary cancer families.
What the study was
- Study design
- Retrospective cohort study (n=500; single-center Italian academic center)
- Population
- BRCA1/2-negative high-risk hereditary cancer families (n=500) referred for genetic counseling
- Sample size
- 500
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Journal of medical genetics
Why it surfaced
Large single-center cohort (n=500) demonstrating utility of expanded exome sequencing beyond BRCA1/2 in hereditary cancer families. Directly supports broader genetic testing implementation in genetic counseling practice. Dell'Elice A, Antonucci I from Università degli Studi Gabriele d'Annunzio.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.